ideaPoint Launches New Partnering-Opportunity Software
Anaqua’s ideaPoint has announced the launch of new software that "will simplify the identification and capture of key partnering opportunities and novel innovative ideas".
The software, ideaPoint 5.0, enables organizations to accelerate the speed and efficiency of evaluating, tracking, and managing innovation and identifying and capitalizing on opportunities for partnerships and collaborations, whether internal or external.
One of the reported key enhancements is Mobile Scout, which enables users to capitalize on potential partnering opportunities more easily and effectively through a mobile device or tablet. Users can quickly capture meetings with potential partners and tag their entries with key information. They can turn meeting notes into opportunities with one click or set reminders to keep track of potential opportunities. In addition, they can easily report on the ROI of events based on leads generated to determine the best way to allocate future resources.
ideaPoint will be presenting the new software at BioEurope on November 5 –7 and participating in the Innovation Roundtable Nov 6– 8, both in Copenhagen, Denmark.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
